Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
Post MS, Rosing J, Van Der Mooren MJ, Zweegman S, Van Baal WM, Kenemans P, Stehouwer CD; Ageing Women' and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU). Post MS, et al. Among authors: van der mooren mj, van baal wm. Br J Haematol. 2002 Dec;119(4):1017-23. doi: 10.1046/j.1365-2141.2002.03957.x. Br J Haematol. 2002. PMID: 12472583 Free article. Clinical Trial.
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD. Post MS, et al. Among authors: van der mooren mj, van baal wm. Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1116-21. doi: 10.1161/01.ATV.0000074146.36646.C8. Epub 2003 May 1. Arterioscler Thromb Vasc Biol. 2003. PMID: 12730085 Clinical Trial.
Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CD, Teerlink T. Post MS, et al. Among authors: van der mooren mj. J Clin Endocrinol Metab. 2003 Sep;88(9):4221-6. doi: 10.1210/jc.2003-030584. J Clin Endocrinol Metab. 2003. PMID: 12970290 Clinical Trial.
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.
Post MS, van der Mooren MJ, van Baal WM, Blankenstein MA, Merkus HM, Kroeks MV, Franke HR, Kenemans P, Stehouwer CD. Post MS, et al. Among authors: van der mooren mj, van baal wm. Am J Obstet Gynecol. 2003 Nov;189(5):1221-7. doi: 10.1067/s0002-9378(03)00599-4. Am J Obstet Gynecol. 2003. PMID: 14634544 Clinical Trial.
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
Vogelvang TE, Mijatovic V, Kenemans P, Emeis JJ, Heijst JA, van der Mooren MJ. Vogelvang TE, et al. Among authors: van der mooren mj. Am J Obstet Gynecol. 2005 Oct;193(4):1384-94. doi: 10.1016/j.ajog.2005.02.083. Am J Obstet Gynecol. 2005. PMID: 16202731 Clinical Trial.
106 results